ÂÜÀòÂÒÂ×

Jessica Kopaczewski is an accomplished clinical operations professional with over 25 years diverse experience in the pharmaceutical research industry supporting global study operations, site management, and personnel management across Phase 1 to IV in a variety of therapeutic indications including liver-related diseases, oncology, and infectious diseases. Prior to joining Galectin Therapeutics, she collaborated with CymaBay Therapeutics to manage operational aspects for their global phase III Primary Biliary Cirrhosis study. Before CymaBay, she consulted with Intercept Pharmaceuticals where she was responsible for the clinical operations oversight of their global phase III fibrosis due to NASH study. Prior positions include CRA functional management at PRA Health Sciences where she held a Leadership role within the BRIDGE CRA On-Boarding Program as a certified Barnett International CRA Training Instructor and was a key contributor to the development of a centralized CRA Quality Assessment Visit Team. Jessica also has prior experience managing global clinical teams from site selection through data analysis, monitoring, and study coordination of both pharmaceutical company-sponsored as well as physician written research trials. She is named as a contributor to several abstracts and posters relating to the treatment of NASH Cirrhosis as well as publications in reputable medical journals relating to the treatment of HIV/AIDs.